8 June 2023

Anti JAKS Biologics EULAR Rheumatoid Arthritis

JAKis don’t beat TNFis in high-risk patients

5 June 2023

Anti JAKS EULAR Rheumatoid Arthritis Sjogren Syndrom

Dual JAK1/TYK2 inhibitor outperforms tofacitinib

5 June 2023

EULAR Lupus Psoriatic Athritis

JAKi fallout reaches PsA guidelines

5 June 2023

EULAR Lupus Osteoporosis

Aussie researchers at EULAR

5 June 2023

Anti JAKS EULAR Rheumatoid Arthritis

CV and cancer risks with JAKi: EULAR perspectives

1 June 2023

EULAR Osteoarthritis

Good news for OA from EULAR

1 June 2023

ARA Rheumatoid Arthritis

Australian quality standard for RA is on its way

1 June 2023

EULAR Osteoarthritis

Sliver of hope for hand OA

1 June 2023

EULAR Spondyloarthritis

EULAR refocuses on coalface patient care

25 May 2023

Biologics giant cell arteritis

Secukinumab promise in GCA

25 May 2023

Lupus Scleroderma

Now it’s scleroderma’s turn for CAR T

18 May 2023

cardiovascular Pharmaceuticals

Beta blockers cut heart attack risk, but not for all

18 May 2023

Polymyalgia Rheumatica Rheumatoid Arthritis Sjogren Syndrom

Autoimmune diseases are on the rise

18 May 2023

Pharmaceuticals Rheumatoid Arthritis

PD-1 checkpoint in play for RA

4 May 2023

Musculoskeletal Pain Research

New hope for chronic low back pain

27 April 2023

Biologics Lupus

Biologics don’t increase infection risk in lupus